Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma
Authors
Keywords
-
Journal
JOURNAL OF PATHOLOGY
Volume 236, Issue 3, Pages 348-359
Publisher
Wiley
Online
2015-03-09
DOI
10.1002/path.4528
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
- (2014) Edward Sausville et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer
- (2014) Emiliano Calvo et al. INVESTIGATIONAL NEW DRUGS
- Osteosarcoma treatment – Where do we stand? A state of the art review
- (2013) Anja Luetke et al. CANCER TREATMENT REVIEWS
- Checkpoint Kinase Inhibitor AZD7762 Overcomes Cisplatin Resistance in Clear Cell Carcinoma of the Ovary
- (2013) Hiroaki Itamochi et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy
- (2013) S. McNeely et al. PHARMACOLOGY & THERAPEUTICS
- Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data
- (2012) Marieke L. Kuijjer et al. GENES CHROMOSOMES & CANCER
- Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer
- (2012) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells
- (2012) H. J. Landau et al. MOLECULAR CANCER THERAPEUTICS
- Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms
- (2012) M Eißmann et al. ONCOGENE
- Activation of ATR and related PIKKs
- (2011) Daniel A. Mordes et al. CELL CYCLE
- Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
- (2011) Jakob K. Anninga et al. EUROPEAN JOURNAL OF CANCER
- Functional characterization of osteosarcoma cell lines provides representative models to study the human disease
- (2011) Alexander B Mohseny et al. LABORATORY INVESTIGATION
- Anticancer therapy with checkpoint inhibitors: what, where and when?
- (2011) Michelle D. Garrett et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair
- (2010) Meredith A. Morgan et al. CANCER RESEARCH
- Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xL
- (2010) Ozgur Kutuk et al. EUROPEAN JOURNAL OF CANCER
- Molecular characterization of commonly used cell lines for bone tumor research: A trans-European EuroBoNet effort
- (2009) Laura Ottaviano et al. GENES CHROMOSOMES & CANCER
- Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss ofCdkn2
- (2009) Alexander B Mohseny et al. JOURNAL OF PATHOLOGY
- Aven-Dependent Activation of ATM Following DNA Damage
- (2008) Jessie Yanxiang Guo et al. CURRENT BIOLOGY
- Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control
- (2008) D. Wilsker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now